---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000021"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T01:07:37.052080+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance

## Summary
- Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.
- GAAP net income $13.9M ($0.14 diluted EPS) vs $32.1M ($0.33) in Q1 2021.
- Non-GAAP net income $29.7M ($0.30 diluted EPS) vs $48.8M ($0.50) prior year.
- Cash and marketable securities $1.2B; reiterates 2022 INGREZZA sales guidance $1.25-$1.35B.
- Positive Phase 3 valbenazine data in Huntington chorea; sNDA filing expected H2 2022.

## SEC filing metadata
- accession: 0000914475-22-000021
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/0000914475-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/nbix-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000021
- JSON: https://secwatch.observer/filing/0000914475-22-000021.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.